Patent · US Active

Treatment of bleeding with low half-life fibrinogen

US8557773B2 · kind B2 · utility

2Cited by

3References

14Claims

0Family size

Assignee

Laboratoire Francais du Fractionnement et des Biotechnologies · FR

Inventors

Frank Pieper · Utrecht, NL
Anurag Relan · Los Angeles, US
Erik Forsberg · Los Angeles, US

Key dates

Filing date	Apr 29, 2009
Grant date	Oct 15, 2013
Priority date	—
Expiry date	Aug 28, 2029

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K14/75
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention provides low-half life fibrinogen with reduced sialyation as a result of recombinant expression or enzymatic and chemical removal. The low-half life fibrinogen is useful in treating or effecting prophylaxis of bleeding particularly in situations of an acute nature in which a high initial dose and rapid decline to normal or below normal levels is desirable.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.